ALTABAX demonstrates superior efficacy in impetigo versus S. aureus* and S. pyogenes.

Results from a placebo-controlled trial

An Advance in Topical Treatment

ALTABAX is the latest advance in topical prescription antibacterials since GSK introduced Bactroban Ointment^® (mupirocin ointment), 2% in 1987. It is the only prescription topical antibacterial with simple 5-day b.i.d. dosing.

Reference:

Bactroban Ointment^® (mupirocin ointment), 2% [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2001.

Important Safety Information

*ALTABAX is indicated for use in adults and pediatric patients aged 9 months and older for the topical treatment of impetigo (up to 100 cm² in total area in adults or 2% total body surface area in pediatric patients aged 9 months or older) due to Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes.

The most common drug-related adverse reaction was application site irritation (1.4% of patients).

Please see complete Prescribing Information for ALTABAX